Floatz logo

Iodixanol

Vulvar, Vaginal, Penile, Rectal Cancer

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Vulvar, Vaginal, Penile, Rectal Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
National Cancer Institute (NCI)
Phase 1/2CCC
pds0101
National Cancer Institute (NCI)
Phase 1/2CCC
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
National Cancer Institute (NCI)
Phase 1/2CCC
Ketorolac Tromethamine
National Cancer Institute (NCI)
Phase 1/2CCC
Epinephrine
National Cancer Institute (NCI)
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Iodixanol is also rated in:

carotid stenosisDormant
B
Indicative ·
63 / 100
View asset →
atherosclerosisDormant
B
Indicative ·
62 / 100
View asset →
Colon CancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →